- Home
- MAMA vs MNPR Comparison
MAMA vs MNPR Comparison
Compare MAMA & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAMA
- MNPR
- Stock Information
- Founded
- MAMA 2010
- MNPR 2014
- Country
- MAMA United States
- MNPR United States
- Employees
- MAMA N/A
- MNPR N/A
- Industry
- MAMA Specialty Foods
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- MAMA Consumer Staples
- MNPR Health Care
- Exchange
- MAMA Nasdaq
- MNPR Nasdaq
- Market Cap
- MAMA 433.3M
- MNPR 390.5M
- IPO Year
- MAMA N/A
- MNPR 2019
- Fundamental
- Price
- MAMA $10.53
- MNPR $99.50
- Analyst Decision
- MAMA Strong Buy
- MNPR Strong Buy
- Analyst Count
- MAMA 3
- MNPR 12
- Target Price
- MAMA $15.33
- MNPR $89.82
- AVG Volume (30 Days)
- MAMA 359.4K
- MNPR 75.8K
- Earning Date
- MAMA 09-08-2025
- MNPR 11-07-2025
- Dividend Yield
- MAMA N/A
- MNPR N/A
- EPS Growth
- MAMA N/A
- MNPR N/A
- EPS
- MAMA 0.11
- MNPR N/A
- Revenue
- MAMA $135,566,000.00
- MNPR N/A
- Revenue This Year
- MAMA $35.35
- MNPR N/A
- Revenue Next Year
- MAMA $28.73
- MNPR N/A
- P/E Ratio
- MAMA $95.39
- MNPR N/A
- Revenue Growth
- MAMA 19.34
- MNPR N/A
- 52 Week Low
- MAMA $5.50
- MNPR $4.50
- 52 Week High
- MAMA $11.49
- MNPR $105.00
- Technical
- Relative Strength Index (RSI)
- MAMA 60.52
- MNPR 87.73
- Support Level
- MAMA $10.10
- MNPR $72.41
- Resistance Level
- MAMA $10.84
- MNPR $101.06
- Average True Range (ATR)
- MAMA 0.46
- MNPR 7.66
- MACD
- MAMA -0.06
- MNPR 2.95
- Stochastic Oscillator
- MAMA 40.00
- MNPR 88.63
About MAMA Mama's Creations Inc.
Mama's Creations Inc is a marketer and manufacturer of fresh deli-prepared foods, found in grocery, mass, club, and convenience stores nationally. The company's broad product portfolio, born from a rich history in Italian foods, now consists of a variety of high-quality, fresh, clean, and easy-to-prepare foods to address the needs of both consumers and retailers. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.